Aspire Biopharma Holdings (ASBP) Revenue (2025 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Revenue came in at $63104.0 in Q2 2026, up 122.57% quarter-over-quarter from $28353.0 in Q1 2026.
Powered by 
Analysis
Aspire Biopharma Holdings (ASBP) Revenue (2025 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Revenue for 2 consecutive years, with $63104.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Revenue changed N/A year-over-year to $63104.0 in Q2 2026; TTM through Jun 2026 was $97659.0, a N/A change from a year earlier, with the FY2025 full-year figure at $6202.0, changed N/A from the prior year.
- Revenue was $63104.0 for Q2 2026 at Aspire Biopharma Holdings, up from $28353.0 in the prior quarter.
- Over five years, Revenue peaked at $63104.0 in Q2 2026 and troughed at $1941.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.46 Bn | 192.47 Bn | 7.24 Bn | 10.05 Bn |
| 2 | Gilead Sciences | 179.92 Bn | 176.75 Bn | 6.22 Bn | 7.80 Bn |
| 3 | Vertex Pharmaceuticals | 131.37 Bn | 123.51 Bn | 2.84 Bn | 3.33 Bn |
| 4 | Regeneron Pharmaceuticals | 81.86 Bn | 73.87 Bn | 3.93 Bn | 4.29 Bn |
| 5 | Argenx Se | 60.29 Bn | 55.10 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 53.76 Bn | 48.62 Bn | 52.00 Mn | 145.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.16 Bn | 29.85 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Biogen | 31.90 Bn | 30.62 Bn | 1.96 Bn | 2.74 Bn |
| 9 | Roivant Sciences | 29.13 Bn | 29.13 Bn | 1.16 Mn | 1.44 Mn |
| 10 | Aspire Biopharma Holdings | 9.27 Mn | -2.90 Mn | -30,086.00 | 63,104.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 63,104.00 |
| Mar 31, 2026 | 28,353.00 |
| Dec 31, 2025 | 4,261.00 |
| Sep 30, 2025 | 1,941.00 |